Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Bank of America Merrill Lynch 2018 Health Care Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on May 17, 2018, at 10:40 a.m. P.T./ 1:40 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Christopher Keenan
VP, Investor Relations and Corporate Communications
[email protected]
650-383-0823
